Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Fax: 202 296 1450

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

SYC80 Dec. 9 at 7:34 AM

$VNDA buying some here

0 · Reply

JazzyJ03 Dec. 9 at 6:20 AM

$VNDA 😌

0 · Reply

small_invester Dec. 9 at 12:27 AM

$VNDA test water with 1500 shares

0 · Reply

HuntingProfit Dec. 8 at 9:59 PM

Momentum is starting to pick up on SAIH ! Looks like ticker SAIH could Squeeze up very soon! It's starting to breakout! This could be the next multi - day runner! Only 500k shares outstanding on SAIH Keep it on watch bulls! SAIH is starting its squeeze up! $SPY $POAI $VNDA $FOXX 0c0-

0 · Reply

BullMarketStocks Dec. 8 at 9:50 PM

$VNDA 👋🏽 new here, added a new position today for 🎲 🎰 PDUFA. Found this as I’m awaiting news on AGIOS. 💪🏽

0 · Reply

Jackie_O_ Dec. 8 at 9:04 PM

$VNDA Great day. Wasn't expecting it this soon, but I'll take it. 🙂

1 · Reply

BullMaven Dec. 8 at 8:56 PM

$VNDA gap to 10+ must be filled

0 · Reply

VixVictor99 Dec. 8 at 8:54 PM

$VNDA catalyst-driven biotech, can gap hard if the next update lands well

0 · Reply

mciuzelis Dec. 8 at 8:27 PM

$VNDA new buyout offer expected?

0 · Reply

Texout Dec. 8 at 8:10 PM

$VNDA someone trying to get on that boat… it’s not late but you must avoid crying or moaning on weaker days until 10+

0 · Reply

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 30, 2025, 9:53 AM EST - 8 days ago

Should You Invest in This Under-the-Radar Weight Loss Stock?

Nov 28, 2025, 7:00 AM EST - 10 days ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 21, 2025, 3:31 AM EST - 18 days ago

Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality

Nov 18, 2025, 10:49 AM EST - 20 days ago

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Nov 17, 2025, 6:37 PM EST - 21 days ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 5, 2025, 5:00 PM EST - 4 weeks ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 10:16 PM EDT - 5 weeks ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:01 PM EDT - 5 weeks ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 6 weeks ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 2 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 2 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 2 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Aug 29, 2025, 3:21 PM EDT - 3 months ago

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Aug 28, 2025, 5:23 PM EDT - 3 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 3 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 4 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Aug 1, 2025, 4:18 AM EDT - 4 months ago

Vanda (VNDA) Q2 Revenue Rises 4%

Jul 31, 2025, 4:45 PM EDT - 4 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 4 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 6 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

May 27, 2025, 9:00 AM EDT - 6 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 16, 2025, 5:30 PM EDT - 7 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 7, 2025, 7:55 PM EDT - 7 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 7 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 7 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 2, 2025, 8:46 AM EDT - 7 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Apr 23, 2025, 3:52 PM EDT - 8 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 7, 2025, 8:00 AM EDT - 8 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Mar 31, 2025, 8:00 AM EDT - 9 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Feb 24, 2025, 7:00 AM EST - 10 months ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 13, 2025, 10:29 PM EST - 10 months ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:01 PM EST - 10 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:30 PM EST - 10 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Jan 27, 2025, 7:00 AM EST - 11 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Jan 8, 2025, 4:17 PM EST - 11 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Dec 20, 2024, 1:26 PM EST - 1 year ago

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Dec 20, 2024, 9:13 AM EST - 1 year ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Dec 16, 2024, 9:29 PM EST - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Nov 12, 2024, 4:58 PM EST - 1 year ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Nov 6, 2024, 8:20 PM EST - 1 year ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:02 PM EST - 1 year ago

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 2:05 PM EDT - 1 year ago

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oct 14, 2024, 10:56 AM EDT - 1 year ago

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Oct 14, 2024, 10:37 AM EDT - 1 year ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 8:19 AM EDT - 1 year ago

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

SYC80 Dec. 9 at 7:34 AM

$VNDA buying some here

0 · Reply

JazzyJ03 Dec. 9 at 6:20 AM

$VNDA 😌

0 · Reply

small_invester Dec. 9 at 12:27 AM

$VNDA test water with 1500 shares

0 · Reply

HuntingProfit Dec. 8 at 9:59 PM

0 · Reply

BullMarketStocks Dec. 8 at 9:50 PM

$VNDA 👋🏽 new here, added a new position today for 🎲 🎰 PDUFA. Found this as I’m awaiting news on AGIOS. 💪🏽

0 · Reply

Jackie_O_ Dec. 8 at 9:04 PM

$VNDA Great day. Wasn't expecting it this soon, but I'll take it. 🙂

1 · Reply

BullMaven Dec. 8 at 8:56 PM

$VNDA gap to 10+ must be filled

0 · Reply

VixVictor99 Dec. 8 at 8:54 PM

$VNDA catalyst-driven biotech, can gap hard if the next update lands well

0 · Reply

mciuzelis Dec. 8 at 8:27 PM

$VNDA new buyout offer expected?

0 · Reply

Texout Dec. 8 at 8:10 PM

$VNDA someone trying to get on that boat… it’s not late but you must avoid crying or moaning on weaker days until 10+

0 · Reply

HoHoHoHum Dec. 8 at 8:07 PM

$VNDA finally getting some traction. Volume strong. RSI on the daily well above 80.

0 · Reply

BullMaven Dec. 8 at 7:53 PM

$VNDA insanely cheap.no brainer to add

0 · Reply

Orlandotrader Dec. 8 at 7:47 PM

$VNDA This decision allows Vanda to extend clinical studies of tradipitant in motion sickness. Separately, the ongoing review of the pending, fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track, with a PDUFA target action date of December 30, 2025, Have a Feeling Mr Market is feeling Pretty Goid about this one.

0 · Reply

jacckkmm Dec. 8 at 7:39 PM

$VNDA boom!!!

0 · Reply

Orlandotrader Dec. 8 at 6:11 PM

$VNDA We Ride!!!

0 · Reply

Texout Dec. 8 at 6:02 PM

$VNDA jus wait for it.My last print in size was $CDTX sub $20… so when I say $10 is the minimum where this should be trading without the regulatory and litigation upside… we will get there and beyond

1 · Reply

Azbkr Dec. 8 at 5:44 PM

$VNDA Grabbed a ton of Jan $6 calls. Like the trajectory going into the catalysts.

0 · Reply

StockBen4444 Dec. 8 at 4:34 PM

$VNDA we have crossed the 52 weeks high, new open highs, nearby 2 PDUFA‘s and one SDNA. I think we are going up now

1 · Reply

FITTEST_RETAIL_TRADER Dec. 8 at 1:12 PM

$VNDA EARLY APPROVAL COMING

1 · Reply

ringo2112 Dec. 8 at 11:20 AM

$VNDA why is this only 5 bucks?...is it waiting for me to buy?...🤣

0 · Reply

FITTEST_RETAIL_TRADER Dec. 8 at 12:15 AM

$VNDA

0 · Reply

Sav_Ryan Dec. 7 at 10:16 PM

$VNDA Should I buy more vnda tomorrow? I already have quite a bit at 5.13.

1 · Reply

Market Cap	318.53M
Revenue (ttm)	198.77M
Net Income (ttm)	-18.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9.51%
Debt to Equity Ratio	0.00

Volume	2,575,800
Avg Vol	822,366
Day's Range	N/A - N/A
Shares Out	59.10M
Stochastic %K	88%
Beta	0.69
Analysts	Strong Sell
Price Target	$11.75